JMJD6 and melanoma: We report here that JMJD6, through regulating PAK1 alternative splicing and influencing the MAPK signaling, through affecting multiple aspects of melanoma cells, promotes melanoma carcinogenesis, supporting the pursuit of JMJD6 as a potential prognostic biomarker and a therapeutic target for melanoma.